Company: AZN
Filing Date: 2025-03-07
Form Type: 6-K
Source: 0001654954-25-002412
Chunk: 7

Company: ASTRAZENECA PLC
Filing Date: 2025-03-07
Form: 6-K
Chunk 7
---
enterol . 2022;28(12):1187-1203.

9. Al-Batran SE, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948-1957.

10. World Health Organization. World Cancer Fact Sheet. Available at https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf

Accessed March 2025.

Dr. Janjigian provides consulting and advisory services to AstraZeneca.

#### Adrian Kemp

#### Company Secretary

#### AstraZeneca PLC
<div align='center'>SIGNATURES</div>

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| AstraZeneca 
 PLC         |

Date: 07 March 2025

| By: /s/           
 Adrian Kemp       |
| Name:             
 Adrian Kemp       |
| Title:            
 Company Secretary |